2nd Closed Scientific Expert Meeting of the Editorial Board

Is Lp(a)-associated cardiovascular risk independent of that associated with LDL-C?

December 5, 2025

Professor Sam Tsimikas, University of California San Diego, USA, considers the evidence supporting Lp(a) as an independent risk factor for atherosclerotic cardiovascular disease.

Elevated Lp(a) and coronary artery disease severity

December 12, 2025

Professor Ulf Landmesser, Charité University Medicine Berlin, Germany, presents research linking higher Lp(a) levels with more severe and complex-to-treat coronary artery disease.

One size fits all? Does the same Lp(a) concentration confer the same cardiovascular risk across ethnicities?

December 2, 2025

Professor Keith Ferdinand, Tulane University School of Medicine, New Orleans, USA, discusses the clinical implications for differences in Lp(a) concentration across ethnicities.

Lp(a)HORIZON cardiovascular outcome trial

December 3, 2025

Professor Steve Nissen, Cleveland Clinic, Ohio, USA, provides an update of the LP(a)HORIZON trial – the first study due to report results of Lp(a) reduction on cardiovascular outcomes.

Update on Phase 2/3 investigations of lepodisiran and muvalaplin

December 5, 2025

Professor Steve Nissen, Cleveland Clinic, Ohio, USA, presents results of the ALPACA trial with lepodisiran and the KRAKEN trial of muvalaplin in patients with elevated Lp(a).

Update on the olpasiran clinical development programme

December 15, 2025

Professor Michelle O’Donoghue, Brigham and Women’s Hospital, Boston, USA, presents data from the Phase 2 OCEAN(a)-DOSE trial and previews the OCEAN(a)-OUTCOMES study.